| Name | Title | Contact Details |
|---|---|---|
Penny Muir |
Associate Director, Compliance | Profile |
Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.
Algorithme Pharma, Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sun BioPharma Inc. is a next-generation biopharmaceutical company developing disruptive therapeutics for serious unmet medical needs. The company`s initial programs are aimed at diseases of the pancreas, including pancreatitis and pancreatic cancer. Sun BioPharma has scientific collaborations with pancreatic disease experts at The Ohio State University, the Fred Hutchinson Cancer Center in Seattle, Translational Genomics (TGen) in Scottsdale, AZ, Cedars Sinai Medical Center in Los Angeles, the University of Minnesota, the Austin Health Cancer Trials Centre and the Box Hill Hospital in Melbourne, Australia and the Ashford Cancer Centre in Adelaide, Australia.
MediPharm Labs was created in 2015 by a handful of industry experts in Ontario. With the medicinal benefits of cannabis firmly established – and with a global patient market demanding quality cannabis oil – MediPharm Labs was born. While initially exploring options to cultivate cannabis plant, MediPharm Labs came to recognize the opportunity for a select focus on cannabis concentrates. MediPharm Labs set out to master this area of production, and rely on the many cultivating experts to provide quality raw materials. In 2016, MediPharm labs submitted an application to Health Canada for approval to distribute medicinal cannabis oil. Proudly, MediPharm Labs was one of the first Licensed Producer applications in history to apply for license that did not include the cultivation of cannabis. The key to MediPharm Labs` unrivaled quality is our best possible use of modern technology and innovative extraction techniques. MediPharm Labs produces cannabis oil that is pharmaceutical grade and and meets the specific quality and purity requirements. The team behind MediPharm Labs have proven industry experience in the areas of pharmaceutical extraction, processing and quality assurance. In 2018, MediPharm Labs is gearing up to commence distribution to our Health Canada approved business partners and make history. The response has been enormous, positive and heartening. Medicinal cannabis has arrived – and through our partners we will provide patients with access to pure, consistent and safe cannabis oil. MediPharm Labs commenced construction of a world-class extraction facility in Australia in June 2018. MediPharm Labs Australia is a subsidiary of MediPharm Labs Inc. and the companies` first expansion outside of Canada. MediPharm Labs Australia completed its application process with the federal Office of Drug Control in February 2018 to extract and import medical cannabis products in Australia.
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.